Abdominal hernia
Conditions
Interventions
Group 0.3: 0.3 mg/kg esketamine will be used during anesthesia induction and the maintenance dose is 0.3 mg/kg/h during the operation.
Group 0.4: 0.4 mg/kg esketamine will be used during anesthesia induction and the maintenance dose is 0.4 mg/kg/h during the operation.
Group 0.5: 0.5 mg/kg esketamine will be used during anesthesia induction and the maintenance dose is 0.5 mg/kg/h during the operation.
Group 0.6: 0.6 mg/kg esketamine will be used during anesthesia induction and the maintenance dose is 0.6 mg/kg/h during the operation.
Group 0.7: 0.7 mg/kg esketamine will be used during anesthesia induction and the maintenance dose is 0.7 mg/kg/h during the operation.
Group of esketamine ( Group K ):Anesthesia will be induced and maintained with an ED 50 dose of esketamine.
Group of opioids ( Group C ): 0.6 ug/kg sufentanil will be used during anesthesia induction and 0.1-0.3 ug/kg/h remifentanil will be used for anesthesia maintenance.
Sponsors
Anqing Municipal Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients undergoing elective laparoscopic herniorrhaphy; 2. Patients over 18 years old; 3. American Society of Anesthesiologists(ASA) Physical Status I-II; 4. New York Heart Association (NYHA) cardiac function is graded I-II; 5. Body Mass Index (BMI) is 18-30 kg/m2.
Exclusion criteria
Exclusion criteria: 1. Patients with liver and /or kidney dysfunction; 2. Patients who are allergic to the drugs used in the research; 3. Patients with previous chronic pain; 4. Patients with increased intracranial pressure or intraocular pressure; 5. Patients with preoperative sinus bradycardia or atrioventricular block; 6. Patients with schizophrenia, mania or any other mental illness; 7. Patients who lack the ability to consent and communicate; 8. Patients who recently take analgesic or sedative drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative pain;The incidence of nausea and vomiting within 48 hours after operation;Plasma cortisol concentration;Plasma TNF-a concentration;Plasma IL-6 concentration;Median effective dose; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time of extubation;The length of staying in the postanesthesia care unit;Length of anesthesia;Length of surgery;Length of postoperative hospital stay;Heart rate;Blood pressure;Pulse oxygen saturation; Time to wake up after anesthesia; | — |
Countries
China
Contacts
Public ContactWang Weibing
Anqing Municipal Hospital
Outcome results
None listed